Angel Uriol
Vice President of Therapeutic Strategy & Client Engagement
Angel Uriol, Vice President of Therapeutic Strategy & Client Engagement at Worldwide Clinical Trials, brings more than 30 years of experience in the pharmaceutical industry, with a specialization in late-stage oncology clinical research and development. His extensive background spans both CRO and pharmaceutical companies, providing a unique perspective on the industry’s diverse needs and challenges.
Ask Angel a question
Submit an RFP. Ask a Question
With a strong foundation in clinical trial management and leadership, Angel has held various significant positions, including VP of Asset Strategy and VP of Clinical Development, Global Oncology, at Syneos Health. He has successfully led global clinical development strategies for oncology programs, managed numerous Phase IIb-IIIb trials across various cancers, and overseen regulatory submissions that have resulted in key drug approvals.
Angel's educational background is robust and relevant to his field. He holds a Pharmacy Degree from Universidad Complutense de Madrid and a Master's in Molecular Oncology from CNIO, Spain. His academic achievements complement his professional expertise, making him a well-rounded expert in oncology drug development.
Throughout his career, Angel has demonstrated expertise in portfolio management, cross-functional team leadership, and business development. His innovative approach to integrating science, operational feasibility, regulatory, and commercial strategy has been instrumental in expediting the delivery of new medicines to patients. As VP of Therapeutic Strategy & Client Engagement, Angel will leverage his extensive experience to drive strategic partnerships and enhance client engagement at Worldwide Clinical Trials.
